# Assessing the Market Readiness for Medical Cannabis in Greece: A Qualitative Study of Patient Perspectives

**Authors:** Christos Ntais, Yioula Melanthiou

PMC · DOI: 10.3390/medicines12020012 · Medicines · 2025-05-09

## TL;DR

This study explores Greek patients' views on medical cannabis, highlighting benefits, concerns, and the need for better education and regulation.

## Contribution

The study provides new qualitative insights into patient perspectives on medical cannabis readiness in Greece.

## Key findings

- CBD-experienced patients find cannabis-based treatments beneficial for pain, migraines, anxiety, and sleep issues.
- Non-users express skepticism but see potential therapeutic value in a regulated system.
- Participants highlight the need for education, training, and clear regulations for responsible market entry.

## Abstract

Background: The introduction of medical cannabis in Greece marks a shift in healthcare policy, yet patient attitudes remain underexplored. Methods: This qualitative study examines the market readiness for medical cannabis through semi-structured interviews with 24 participants—12 users of cannabidiol (CBD)-based formulations and 12 medical cannabis-naive individuals. Results: CBD-experienced patients generally perceive cannabis-based treatments as beneficial for managing musculoskeletal pain, migraines, anxiety, stress and sleep disturbances, despite concerns over product quality, cost and limited medical guidance. Medical cannabis-naive participants express skepticism due to stigma and perceived insufficient evidence but acknowledge potential therapeutic value within a regulated framework. This study highlights the need for better patient education, physician training and clear regulatory guidelines to support responsible market entry. Conclusions: These findings offer important insights for policymakers, healthcare providers and the pharmaceutical industry, emphasizing the need for a structured, evidence-based approach to medical cannabis integration in Greece. Further research is needed to assess long-term patient experiences and the evolving impact of regulatory changes on market dynamics.

## Linked entities

- **Chemicals:** cannabidiol (PubChem CID 644019), CBD (PubChem CID 644019)
- **Diseases:** anxiety (MONDO:0005618), sleep disturbances (MONDO:0100081)

## Full-text entities

- **Diseases:** migraines (MESH:D008881), sleep disturbances (MESH:D012893), anxiety (MESH:D001007), musculoskeletal pain (MESH:D059352)
- **Chemicals:** CBD (MESH:D002185)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12101335/full.md

## References

25 references — full list in the complete paper: https://tomesphere.com/paper/PMC12101335/full.md

---
Source: https://tomesphere.com/paper/PMC12101335